Dagan et al. [47] assessed the relevance of AR CAG repeat length and ovarian cancer risk in Jewish Israeli women who are BRCA1/2 mutation carriers, and null results were concluded, most likely due to the small sample size. This evidence concerns the gene BRCA1 and ovarian cancer.